These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 27676279)

  • 1. Current management of low-grade gliomas.
    Hottinger AF; Hegi ME; Baumert BG
    Curr Opin Neurol; 2016 Dec; 29(6):782-788. PubMed ID: 27676279
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation and chemotherapy for high-risk lower grade gliomas: Choosing between temozolomide and PCV.
    McDuff SGR; Dietrich J; Atkins KM; Oh KS; Loeffler JS; Shih HA
    Cancer Med; 2020 Jan; 9(1):3-11. PubMed ID: 31701682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of 1p/19q codeletion and histology on outcomes of anaplastic gliomas treated with radiation therapy and temozolomide.
    Speirs CK; Simpson JR; Robinson CG; DeWees TA; Tran DD; Linette G; Chicoine MR; Dacey RG; Rich KM; Dowling JL; Leuthardt EC; Zipfel GJ; Kim AH; Huang J
    Int J Radiat Oncol Biol Phys; 2015 Feb; 91(2):268-76. PubMed ID: 25636755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive Genomic Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation Versus Radiation Plus Procarbazine, Lomustine (CCNU), and Vincristine in High-Risk Low-Grade Glioma.
    Bell EH; Zhang P; Shaw EG; Buckner JC; Barger GR; Bullard DE; Mehta MP; Gilbert MR; Brown PD; Stelzer KJ; McElroy JP; Fleming JL; Timmers CD; Becker AP; Salavaggione AL; Liu Z; Aldape K; Brachman DG; Gertler SZ; Murtha AD; Schultz CJ; Johnson D; Laack NN; Hunter GK; Crocker IR; Won M; Chakravarti A
    J Clin Oncol; 2020 Oct; 38(29):3407-3417. PubMed ID: 32706640
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy for adult low-grade gliomas: clinical outcomes by molecular subtype in a phase II study of adjuvant temozolomide.
    Wahl M; Phillips JJ; Molinaro AM; Lin Y; Perry A; Haas-Kogan DA; Costello JF; Dayal M; Butowski N; Clarke JL; Prados M; Nelson S; Berger MS; Chang SM
    Neuro Oncol; 2017 Feb; 19(2):242-251. PubMed ID: 27571885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
    Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
    J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of patients with recurrence of diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline.
    Nahed BV; Redjal N; Brat DJ; Chi AS; Oh K; Batchelor TT; Ryken TC; Kalkanis SN; Olson JJ
    J Neurooncol; 2015 Dec; 125(3):609-30. PubMed ID: 26530264
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide.
    Wick W; Roth P; Hartmann C; Hau P; Nakamura M; Stockhammer F; Sabel MC; Wick A; Koeppen S; Ketter R; Vajkoczy P; Eyupoglu I; Kalff R; Pietsch T; Happold C; Galldiks N; Schmidt-Graf F; Bamberg M; Reifenberger G; Platten M; von Deimling A; Meisner C; Wiestler B; Weller M;
    Neuro Oncol; 2016 Nov; 18(11):1529-1537. PubMed ID: 27370396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
    Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
    Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas.
    Aoki K; Nakamura H; Suzuki H; Matsuo K; Kataoka K; Shimamura T; Motomura K; Ohka F; Shiina S; Yamamoto T; Nagata Y; Yoshizato T; Mizoguchi M; Abe T; Momii Y; Muragaki Y; Watanabe R; Ito I; Sanada M; Yajima H; Morita N; Takeuchi I; Miyano S; Wakabayashi T; Ogawa S; Natsume A
    Neuro Oncol; 2018 Jan; 20(1):66-77. PubMed ID: 29016839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-grade gliomas.
    Schiff D
    Continuum (Minneap Minn); 2015 Apr; 21(2 Neuro-oncology):345-54. PubMed ID: 25837900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiotherapy versus radiotherapy combined with temozolomide in high-risk low-grade gliomas after surgery: study protocol for a randomized controlled clinical trial.
    Wang J; Wang Y; He Y; Guan H; He L; Mu X; Peng X
    Trials; 2019 Nov; 20(1):641. PubMed ID: 31752981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemotherapy in low-grade gliomas.
    Viaccoz A; Lekoubou A; Ducray F
    Curr Opin Oncol; 2012 Nov; 24(6):694-701. PubMed ID: 22913972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular predictors of outcome in low-grade glioma.
    Weiler M; Wick W
    Curr Opin Neurol; 2012 Dec; 25(6):767-73. PubMed ID: 23160425
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
    Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
    J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
    Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
    J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma.
    Tom MC; Park DYJ; Yang K; Leyrer CM; Wei W; Jia X; Varra V; Yu JS; Chao ST; Balagamwala EH; Suh JH; Vogelbaum MA; Barnett GH; Prayson RA; Stevens GHJ; Peereboom DM; Ahluwalia MS; Murphy ES
    Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):1106-1112. PubMed ID: 31461674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a three-long non-coding RNA signature for predicting survival of temozolomide-treated isocitrate dehydrogenase mutant low-grade gliomas.
    Li R; Chen W; Mao P; Wang J; Jing J; Sun Q; Wang M; Yu X
    Exp Biol Med (Maywood); 2021 Jan; 246(2):187-196. PubMed ID: 33028081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide for low-grade gliomas: predictive impact of 1p/19q loss on response and outcome.
    Kaloshi G; Benouaich-Amiel A; Diakite F; Taillibert S; Lejeune J; Laigle-Donadey F; Renard MA; Iraqi W; Idbaih A; Paris S; Capelle L; Duffau H; Cornu P; Simon JM; Mokhtari K; Polivka M; Omuro A; Carpentier A; Sanson M; Delattre JY; Hoang-Xuan K
    Neurology; 2007 May; 68(21):1831-6. PubMed ID: 17515545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.